Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited is an Australia-based drug repurposing company.
The business
Island Pharmaceuticals Limited is an Australia-based drug repurposing company. The Company is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
Small Caps Research
No research on Island Pharmaceuticals Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise ILA based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Island Pharmaceuticals Builds Galidesivir Inventory for Outbreak Response
Island Pharmaceuticals expands Galidesivir stock with a second GMP campaign, targeting 700-800 treatment courses by Q4 2026 as Bundibugyo Ebola spreads; MEURI.
Island Pharmaceuticals Expands USAMRIID Agreement for Galidesivir Marburg Study
Island Pharmaceuticals expands USAMRIID CRADA to dose-optimise Galidesivir Marburg study; trials start next quarter; topline results H2 2026, a major milestone.
Island Pharmaceuticals Strengthens Biodefence Engagement for Galidesivir Advancement
Island Pharmaceuticals strengthens US biodefence push with new adviser Mark Herzog, MC2 roles, and Galidesivir progress toward FDA Animal Rule trials.
Island Pharma Expands Antiviral Pipeline with Burnet Institute Collaboration and NHMRC Funding
Island Pharma expands antiviral pipeline with Burnet Institute; NHMRC grant of over $780k to back ISLA-101, accelerating Galidesivir MVD program.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.